Skip to Content
Merck
CN
All Photos(1)

Documents

1269243

USP

Famotidine Related Compound D

United States Pharmacopeia (USP) Reference Standard

Sign Into View Organizational & Contract Pricing
All Photos(1)
Synonym(s):
3-{{{2-[(Diaminomethylene)amino]thiazol-4-yl}methyl}sulphanyl}propanamide, 3-[[[2-[(Aminoiminomethyl)amino]-4-thiazolyl]methyl]thio]propanamide
Empirical Formula (Hill Notation):
C8H13N5OS2
CAS Number:
76824-16-3
Molecular Weight:
259.35
UNSPSC Code:
41116107
NACRES:
NA.24

biological source

synthetic

grade

pharmaceutical primary standard

Agency

USP

API family

famotidine

form

powder

packaging

pkg of 25 mg

manufacturer/tradename

USP

storage condition

protect from light

color

white

application(s)

pharmaceutical (small molecule)

format

neat

storage temp.

2-8°C

InChI

1S/C8H13N5OS2/c9-7(14)1-2-15-3-6-4-16-8(13-6)11-5-12-10/h4-5H,1-3,10H2,(H2,9,14)(H,11,12,13)

InChI key

ASHSLSDRNNWQKI-UHFFFAOYSA-N

Looking for similar products? Visit Product Comparison Guide

Related Categories

General description

Famotidine Related Compound D (Famotidine Impurity D) is an impurity of famotidine, which is a hydrophilic, cationic, histamine H2 receptor antagonist drug that effectively inhibits gastric acid secretion in humans.
This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Famotidine Related Compound D can be used as a pharmaceutical primary standard for the determination of the analyte in pharmaceutical formulations by various analytical techniques.

Analysis Note

These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.  ​

Other Notes

Sales restrictions may apply.

related product

Product No.
Description
Pricing

PHR1055

Famotidine, Pharmaceutical Secondary Standard; Certified Reference Material

F0005000

Famotidine, European Pharmacopoeia (EP) Reference Standard

Y0000409

Famotidine impurity D, European Pharmacopoeia (EP) Reference Standard

Y0000382

Famotidine for system suitability, European Pharmacopoeia (EP) Reference Standard

1269200

Famotidine, United States Pharmacopeia (USP) Reference Standard

1269265

Famotidine Related Compound F, United States Pharmacopeia (USP) Reference Standard

1269221

Famotidine Related Compound B, United States Pharmacopeia (USP) Reference Standard

1269232

Famotidine Related Compound C, United States Pharmacopeia (USP) Reference Standard

1269254

Famotidine Related Compound E, United States Pharmacopeia (USP) Reference Standard

BP653

Famotidine, British Pharmacopoeia (BP) Reference Standard

PHR2908

Famotidine Related Compound F, certified reference material, pharmaceutical secondary standard

PHR2909

Famotidine Related Compound B, certified reference material, pharmaceutical secondary standard

PHR2910

Famotidine Related Compound C

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Stability indicating method for famotidine in pharmaceuticals using porous graphitic carbon column
Helali N and Monser L
Journal of Separation Science, 31(2) (2008)
Capillary zone electrophoresis method for the determination of famotidine and related impurities in pharmaceuticals
Helali N, et al.
Talanta, 74(4) (2008)
Famotidine
Pharmacopeia, US
United States Pharmacopeia, 39(1)(1-2), 1815-1815 (2020)
Potentiometric determination of famotidine in pharmaceutical formulations
Ayad MM, et al.
Journal of Pharmaceutical and Biomedical Analysis, 29(1-2) (2002)
RP-HPLC determination of famotidine and its potential impurities in pharmaceuticals
Helali N, et al.
Chromatographia, 60(7-8) (2004)
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service